Abstract
Nurr1 is a member of the nuclear receptor superfamily and is a potential susceptibility gene for Parkinson’s disease (PD). Several lines of studies in vitro and in vivo reported that defects in the Nurr1 gene cause nigrostriatal neuronal deficiency as seen in PD. In the present study, we used a a synthetic low molecular weight Nurr1 activator which increases the transcription of Nurr1 to investigate whether it has anti-parkinsonian effects against nigrostriatal neuronal degeneration induced by proteasome inhibitor lactacystin. Adult C57BL/6 mice were treated orally with the Nurr1 activator and an inactive structural analog as a control at a dose of 10mg/kg per day, starting 3 days before microinjection of proteasome inhibitor lactacystin into the medial forebrain bundle and the treatment continued for a total of 4 weeks. Animal behavior tests, and pathological and biochemical examinations were performed to determine the anti-parkinsonian effects of the Nurr1 activator. We found that treatment with the Nurr1 activator significantly improved rotarod performance, attenuated dopamine neuron loss and nigrostriatal dopamine reduction, increased expression of Nurr1, dopamine transporter and vesicular monoamine transporter 2, and alleviated microglial activation in the substantia nigra of lactacystin-lesioned mice. These results suggest that the Nurr1 activator may become an innovative strategy for the treatment of PD.
Keywords: Lactacystin; Inflammation; Neuroprotection; Nurr1 gene activator; Parkinson’s disease; ubiquitin-proteasome system, Dopamine, Dopamine transporter, 4-dihydroxy-phenylacetic acid, RT-PCR,
CNS & Neurological Disorders - Drug Targets
Title:Anti-Parkinsonian Effects of Nurr1 Activator in Ubiquitin-Proteasome System Impairment Induced Animal Model of Parkinson’s Disease
Volume: 11 Issue: 6
Author(s): Zhen Zhang, Xuping Li, Wen-jie Xie, Houzhen Tuo, Samuel Hintermann, Joseph Jankovic and Weidong Le
Affiliation:
Keywords: Lactacystin; Inflammation; Neuroprotection; Nurr1 gene activator; Parkinson’s disease; ubiquitin-proteasome system, Dopamine, Dopamine transporter, 4-dihydroxy-phenylacetic acid, RT-PCR,
Abstract: Nurr1 is a member of the nuclear receptor superfamily and is a potential susceptibility gene for Parkinson’s disease (PD). Several lines of studies in vitro and in vivo reported that defects in the Nurr1 gene cause nigrostriatal neuronal deficiency as seen in PD. In the present study, we used a a synthetic low molecular weight Nurr1 activator which increases the transcription of Nurr1 to investigate whether it has anti-parkinsonian effects against nigrostriatal neuronal degeneration induced by proteasome inhibitor lactacystin. Adult C57BL/6 mice were treated orally with the Nurr1 activator and an inactive structural analog as a control at a dose of 10mg/kg per day, starting 3 days before microinjection of proteasome inhibitor lactacystin into the medial forebrain bundle and the treatment continued for a total of 4 weeks. Animal behavior tests, and pathological and biochemical examinations were performed to determine the anti-parkinsonian effects of the Nurr1 activator. We found that treatment with the Nurr1 activator significantly improved rotarod performance, attenuated dopamine neuron loss and nigrostriatal dopamine reduction, increased expression of Nurr1, dopamine transporter and vesicular monoamine transporter 2, and alleviated microglial activation in the substantia nigra of lactacystin-lesioned mice. These results suggest that the Nurr1 activator may become an innovative strategy for the treatment of PD.
Export Options
About this article
Cite this article as:
Zhang Zhen, Li Xuping, Xie Wen-jie, Tuo Houzhen, Hintermann Samuel, Jankovic Joseph and Le Weidong, Anti-Parkinsonian Effects of Nurr1 Activator in Ubiquitin-Proteasome System Impairment Induced Animal Model of Parkinson’s Disease, CNS & Neurological Disorders - Drug Targets 2012; 11 (6) . https://dx.doi.org/10.2174/187152712803581155
DOI https://dx.doi.org/10.2174/187152712803581155 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Natural Steroids and Androgen Antagonists used as Neuroprotection in Common Neurological Disorders
CNS & Neurological Disorders - Drug Targets The Neuropsychological Hypothesis of Antidepressant Drug Action Revisited
CNS & Neurological Disorders - Drug Targets Fluorescent Dyes for Bio-Applications in the Patent Literature
Recent Patents on Materials Science The Role of Androgen Receptor Mutations in Prostate Cancer Progression
Current Genomics Structural Characterization, Homology Modeling and Docking Studies of ARG674 Mutation in MyH8 Gene Associated with Trismus-Pseudocamptodactyly Syndrome
Letters in Drug Design & Discovery Pelletization Processes for Pharmaceutical Applications: A Patent Review
Recent Patents on Drug Delivery & Formulation Clearance of Beta-Amyloid in the Brain
Current Medicinal Chemistry Inflammation, Hyperinflammation & Cystic Fibrosis Lung Disease – A Paradigm Shift?
Current Respiratory Medicine Reviews Human Lipoxygenase: Developments in its Structure, Function, Relevance to Diseases and Challenges in Drug Development
Current Medicinal Chemistry Oxidative Stress, Mitochondrial Dysfunction, and Stress Signaling in Alzheimers Disease
Current Alzheimer Research CFTR and MDR: ABC Transporters with Homologous Structure but Divergent Function
Current Genomics Current Options and Perspectives in the Treatment of Diabetic Neuropathy
Current Pharmaceutical Design Apoptosis Induction by Ultrasound and Microbubble Mediated Drug Delivery and Gene Therapy
Current Molecular Medicine Why do Psychotic Patients use Cannabis? Case Series
Current Pharmaceutical Design The Clinical Development of γ-Hydroxybutyrate (GHB)
Current Drug Safety Targeting SKCa Channels in Cancer: Potential New Therapeutic Approaches
Current Medicinal Chemistry Adult Neurogenesis: Can Analysis of Cell Cycle Proteins Move Us “Beyond BrdU”?
Current Pharmaceutical Biotechnology Biosensors for Screening Kinase Inhibitors
Current Topics in Medicinal Chemistry Cannabinoid Modulation of Fear Extinction Brain Circuits: A Novel Target to Advance Anxiety Treatment
Current Pharmaceutical Design Novel Insights in Molecular Mechanisms of CLL
Current Pharmaceutical Design